Requires Division of Consumer Affairs display list of all registered ticket brokers on division's website.
Impact
The passage of S518 would amend existing laws governing the prescription monitoring program, specifically P.L.2007, c.244. By granting patients the option to request a notation against the prescribing of specific medications, it promotes a proactive approach to patient care that could significantly aid individuals recovering from substance addiction or those at risk of misuse. The bill mandates that healthcare providers incorporate educational measures to ensure they are aware of and effectively enact this patient preference system, fostering improved communication within healthcare settings regarding opioid prescriptions.
Summary
S518, introduced in the New Jersey Legislature, focuses on enhancing the prescription monitoring program by allowing patients to indicate preferences regarding the prescription of opiate medications and other controlled substances. This bill aims to establish a formal process whereby patients can request that their prescription monitoring information reflect their wish not to receive certain medications known for their potential for abuse. These preferences are only included with the patient's consent, emphasizing patient autonomy in medical decisions related to potentially addictive substances.
Sentiment
General sentiment regarding S518 appears to lean positive among advocates for patient rights and addiction recovery programs. Supporters argue that the bill empowers patients and improves safety by mitigating the risks of prescription drug misuse. However, there are concerns among critics regarding the potential challenges healthcare providers may face when navigating patients’ requests, particularly in emergency situations where timely medication may be crucial.
Contention
Notable points of contention include the framework for effectively communicating patient preferences in cases of incapacitation, as well as the implications this may have on emergency medical decisions. Some stakeholders express concern that the inability to prescribe necessary medication based on a patient's prior preference could lead to adverse health outcomes. Moreover, discussions around the implementation process emphasize the necessity for strict guidelines and training to ensure that healthcare providers are equipped to handle these new requirements without compromising patient care.
Requires certain notice when redirecting consumers to website for ticket resale and establishes certain requirements for websites offering tickets for resale.
Requires reporting agencies to report to Division of Consumer Affairs number of free consumer reports furnished to New Jersey resident consumers annually.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.